SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

TMC the metals co., Inc. is a deep-sea minerals exploration company focused on the collection and processing of polymetallic nodules found on the seafloor in international waters of the Clarion Clipperton Zone in the Pacific Ocean (CCZ). These nodules contain high grades of four metals (nickel, copper, cobalt, manganese) which can be used as (i) feedstock for battery cathode precursors (nickel, cobalt and manganese sulfates, or intermediate nickel-copper-cobalt matte) for electric vehicles (EV) and renewable energy storage markets, (ii) copper cathode for EV wiring, energy transmission and other applications and (iii) manganese silicate for manganese alloy production required for steel production. The company was founded in 2021 and is headquartered in Vancouver, Canada.

TMC the metals company Inc

TMC is trending amid discussion of deep sea mining's potential and recent UBS and Nature articles highlighting the value of deep sea mineral resources. Community members are actively debating price targets, potential for a short squeeze, and the company's long-term prospects in the critical minerals sector, especially in relation to shipbuilding and defense. Some investors are also weighing the impact of potential government stakes and regulatory decisions on TMC's future.

Direxion Shares ETF Trust - Direxion Daily S&P Biotech Bull 3X Shares

Direxion Daily S&P Biotech Bull 3X Shares

LABU is trending as biotech sees a surge in interest, fueled by AI advancements and potential sector rotation, though some caution that the rally may be overextended. The community is debating whether current bullish sentiment is sustainable, considering factors like upcoming economic data and geopolitical events. Discussions also include individual stock analyses and potential impacts of rate cuts and tariff policies on the sector.

Orca is the most user-friendly DEX on Solana.  Orca is one of the first general-purpose AMMs launched on Solana. Users can swap assets, provide liquidity, and earn yield through an easy-to-use interface. Projects can use Orca as a money-lego to easily integrate swapping, farming, or on-chain data into their dApp.  Orca strives to provide easy and effective financial tools for everyone, bringing DeFi to the masses.

Orca

ORCA is trending as traders discuss potential breakout levels and upcoming catalysts, while some community members are assessing ideal entry points and long-term recovery prospects. There's excitement building around its potential within the Solana ecosystem and predictions for substantial gains, with some eyeing a move past $3 as key to unlocking further upward momentum. Community members are also discussing recent developments in Orca's Dynamic Tick Arrays and Adaptive Fees, which could lead to tighter spreads, more liquidity, and strategic advantages during market volatility.

ServiceNow, Inc. engages in the provision of an end-to-end workflow automation platform for digital businesses. Its Now Platform is a cloud-based solution embedded with artificial intelligence (AI) and machine learning (ML). The company was founded by Frederic B. Luddy in June 2004 and is headquartered in Santa Clara, CA.

ServiceNow Inc

ServiceNow is trending amid discussions of a potential acquisition of a security startup and community anticipation for a stock split, even as some express concerns about recent price action. Despite a year-to-date decline, some investors view NOW's AI capabilities as undervalued compared to peers like Microsoft, while others debate whether the company can translate AI investments into top-line growth. Option activity and analyst ratings remain mixed, contributing to the ongoing community discussion.

ETF Opportunities Trust - T-REX 2X Long BMNR Daily Target ETF

T-REX 2X Long BMNR Daily Target ETF

$BMNU is trending due to its leveraged exposure to $BMNR, attracting traders aiming to amplify potential gains from a rebound in the crypto market, particularly Ethereum. Community members are actively discussing entry points, profit-taking strategies, and its potential for significant upward movement, with some expressing concerns about its tracking accuracy relative to $BMNR and potential reverse splits.

Zscaler, Inc. engages in the provision of a cloud-based internet security platform. It offers Zero Trust Exchange, Zscaler Client Connector, Zscaler Internet Access, Zscaler Private Access, Zscaler B2B, Zscaler Cloud Protection, and Zscaler Digital Experience. The company was founded by Jagtar Singh Chaudhry and K. Kailash in September 2007 and is headquartered in San Jose, CA.

Zscaler Inc

ZS is trending due to its recent earnings report and subsequent analyst activity, with community members discussing whether the stock's reaction is an overdone sell-off or a justified correction. Despite positive earnings, some investors are concerned about guidance and valuation, while others see it as a buying opportunity. Broader sector trends and AI security are also influencing the conversation around ZS.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

AUPH is trending amid buyout speculation and positive Q3 earnings, which showcased strong Lupkynis sales growth and promising progress with AUR200. Community discussions revolve around potential BO prices, patent extension timelines, and the impact of recent developments surrounding a former FDA official. Optimism is fueled by increased institutional ownership and analysts raising price targets, though the community remains wary due to the stock's volatile history.

SMX (Security Matters) Plc is a holding company, which engages in the provision of authentication solutions. It offers brand protection, authentication, and track and trace technology. The company was founded by Haggai Alon on July 1, 2022 and is headquartered in Dublin, Ireland.

SMX (Security Matters) Plc

SMX (Security Matters) Public Ltd Co - Ordinary Shares - Class A

SMX is trending due to a recent Zacks Small Cap Research report and speculation of a short squeeze, sparking bullish sentiment. The community is actively discussing the potential for further gains, referencing its unique technology and recent partnerships, while some caution against potential dilution and past reverse splits. High short borrow fees and low float are contributing to the intense trading activity.

Symbotic, Inc. is an automation technology company, which engages in a robotics and automation-based product movement technology platform. It focuses on developing, commercializing, and deploying innovative, end-to-end technology solutions for supply chain operations. It operates through the United States and Canada geographical segments. The company was founded by Richard B. Cohen on December 11, 2020 and is headquartered in Wilmington, MA.

Symbotic Inc - Ordinary Shares - Class A

Symbotic Inc 

Symbotic ($SYM) is trending as traders discuss its bullish market structure and potential for a significant price surge, fueled by volume-backed rallies and comparisons to other high-growth stocks. Community members are analyzing revenue multiples, anticipating a short squeeze, and eyeing potential price targets, contributing to the increased attention on the stock. Bullish sentiment appears to be dominating discussions surrounding the AI-driven robotics and automation company.

Amentum Holdings, Inc. provides mission-critical, technology-driven services in government and commercial markets. It operates through two operating segments: Critical Mission Solutions and Cyber & Intelligence. The Critical Mission Solutions segment provides test, training, and operations services for missile defense systems, IT and engineering services to defense clients and the space sector, technological solutions, including installations, decommissioning, and environmental remediation to energy clients, and other highly technical consulting solutions. The Cyber & Intelligence segment provides advanced cyber training and data analytics for government professionals, advanced communication systems and aerial mapping technologies to national security clients, and other technical services for United States defense and intelligence clients. The company was founded on November 26, 2019 and is headquartered in Chantilly, VA.

Amentum Holdings Inc.

AMTM is trending due to a combination of factors, including recent analyst upgrades and mentions of a potential pro-nuclear energy stance. Bullish sentiment is fueled by the company's strong presence in the nuclear sector and significant government contracts, with the community discussing its potential for growth and comparing it to other high-performing stocks.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Why the underdog mindset could be your business superpower

You can catch Warrior Money on Apple Podcasts, Spotify, Amazon Music, or wherever you get your podcasts. What does it take to go from refugee kid to Marine pilot, biotech CEO, and author? On this...

Cadrenal Therapeutics, Inc.  

Cadrenal Therapeutics, Inc. (CVKD) on Monday announced the acquisition of new assets from eXIthera Pharmaceuticals.The company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/09/15/3149938/0/en/Cadrenal-Therapeutics-Enhances-Anticoagulation-Pipeline-Through-Acquisition-of-eXIthera-s-Portfolio-of-Factor-XIa-Inhibitors.html">said</a> that the acquisition will significantly enhance its pipeline by adding novel assets in acute and chronic anticoagulation settings. As per the deal, eXIthera will receive milestone payments from Cadrenal totaling up to $15 million, subject to the realization of certain future clinical and regulatory milestones. eXIthera will also be entitled to royalties on global sales of the acquired assets upon future commercialization.CVKD shares jumped 2% at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/CVKD">CVKD stock</a> fell from ‘bullish’ to ‘neutral’ territory over the past 24 hours, while message volume stayed at ‘low’ levels.The deal includes eXIthera’s portfolio of investigational intravenous (IV) and oral Factor XIa inhibitors, a new class of anticoagulants. This includes eXIthera’s lead asset, Frunexian, being studied for acute anticoagulation, EP-7327, an oral small molecule candidate for chronic indications, and an extensive portfolio of additional small molecules.“With this acquisition, Cadrenal is the only company in the world developing a novel vitamin K antagonist (tecarfarin) and Factor XIa inhibitors, a promising new class of anticoagulants,” said Cadrenal CEO Quang X. Pham.“With tecarfarin planning a trial in patients with end-stage kidney disease transitioning to dialysis, our plans for LVAD patients, and the current addition of frunexian and EP-7327, we believe that Cadrenal is strategically positioned to deliver differentiated therapeutics across the entire spectrum of patients with cardiovascular thrombotic risk,” he added.Sichuan Haisco Pharmaceuticals retains rights to Frunexian in China under a pre-existing license agreement, the company said. Cadrenal will, however, be entitled to receive royalties of Frunexian sales in China.CVKD stock is down 8% this year but up approximately 20% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/trump-fed-rate-cut-this-week-too-late-powell-bigger-than-he-had-in-mind/chwwONNRdUh">Trump Says ‘Too Late’ Powell Must Cut Rates Now, And ‘Bigger Than He Had In Mind’ Ahead Of Fed Meeting This Week</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Cadrenal Therapeutics Expands Pipeline With Portfolio Acquisition Worth Up To $15 Million

The company said that the acquisition will significantly enhance its pipeline by adding novel assets in acute and chronic anticoagulation settings.

Equity

Cadrenal Therapeutics Announces Chief Medical Officer Transition to Advance Clinical Development of Tecarfarin

Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company focused on the development of specialized cardiovascular therapies, with the late-stage asset tecarfarin, a new...

Cadrenal Therapeutics to Present at BIO CEO & Investor Conference

Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company focused on the development of specialized cardiovascular therapies, leading with tecarfarin, a new Vitamin K...

Cadrenal Therapeutics to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025

Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), today announced that Chairman and Chief Executive Officer, Quang X. Pham, will participate in a webcasted fireside chat at the Lytham Partners 2025...

Cadrenal Therapeutics Provides 2024 Year-End Company Update, Reinforcing Clinical Development Plan for Tecarfarin in LVAD and Other Rare Cardiovascular Indications

Cadrenal Therapeutics, Inc. (Nasdaq: CVKD) today recapped its 2024 milestones and highlighted a clear path forward to develop the investigational drug tecarfarin as a superior and safer chronic...

Cadrenal Therapeutics Gears Up for the 43rd Annual J.P. Morgan Healthcare Conference Week with Event Participation and Investor/Partner Meetings

Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), announced today its engagement in three key events leading up to and during the 43rd Annual J.P. Morgan Healthcare Conference Week, to be held on January...

Cadrenal Therapeutics Named Anticoagulation Therapy Company of the Year by Pharma Tech Outlook

Cadrenal Therapeutics Named Anticoagulation Therapy Company of the Year by Pharma Tech Outlook Cadrenal Therapeutics Named Anticoagulation Therapy Company of the Year by Pharma Tech Outlook PR...

CADRENAL THERAPEUTICS PROVIDES THIRD-QUARTER CORPORATE UPDATE

CADRENAL THERAPEUTICS PROVIDES THIRD-QUARTER CORPORATE UPDATE CADRENAL THERAPEUTICS PROVIDES THIRD-QUARTER CORPORATE UPDATE PR Newswire PONTE VEDRA, Fla., Nov. 7, 2024 PONTE VEDRA, Fla., Nov. 7, 2024...

Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel therapy. It develops tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was founded by Quang X. Pham and Matthew K. Szot on January 25, 2022 and is headquartered in Ponte Vedra, FL.

Current Price	$9.29
Prev Close	$9.92
Open	$9.90
Dividend Yield	0.00%
50-Day Moving Average	$12.87
Beta	0.95
Avg. Volume	25,589.22
PE Ratio	-1.17

52-Week High	$22.90
52-Week Low	$8.74
Market Capitalization	$20.59M
EPS (Annual)	-$8.73
Price to Book	7.06
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

CVKD
Cadrenal Therapeutics, Inc.

Feed

News

Sentiment

Fundamentals

Info

Latest CVKD News

CVKDCadrenal Therapeutics, Inc.